JL516. Management of Cytokine Release Syndrome and Neurologic Events in ZUMA-1: Anti-CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel (axi-cel), in Patients With Refractory, Aggressive Non-Hodgkin Lymphoma. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.